Dr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.
Please enable it in your browser's preferences.
You can visit our support center if you're having problems.
We recommend upgrading to the latest
Page load failed
Please check your internet connection and refresh the page. You might also try disabling any ad blockers.